Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 547
Rev. cient. cienc. salud ; 6: 1-7, 30-01-2024.
Article in Spanish | LILACS, BDNPAR | ID: biblio-1532702


El interrogatorio sobre hábito tabáquico no debe obviarse jamás, pues el abanico de posibilidades diagnósticas inherentes es amplio. Es un gesto clínico fundamental frente a individuos que consultan por síntomas y/o hallazgos radiológicos casuales. Presentamos tres casos clínicos: síndrome de combinación de fibrosis pulmonar y enfisema, neumonitis intersticial descamativa e histiocitosis de células de Langerhans, como parte del abanico de las enfermedades pulmonares intersticiales difusas asociadas a tabaco (EPIDAT), donde la tomografía de alta resolución de tórax tiene un rol destacado. Palabras clave: tabaquismo; enfisema; enfermedades pulmonares intersticiales; histiocitosis de células de Langerhans

Questioning about smoking habits should never be ignored, since the range of inherent diagnostic possibilities is wide. It is a fundamental clinical step facing individuals who consult for symptoms and/or casual radiological findings. We present three clinical cases: the combined syndrome of pulmonary fibrosis and emphysema, desquamative interstitial pneumonitis, and Langerhans cell histiocytosis, as part of the range of tobacco-associated diffuse interstitial lung diseases (EPIDAT), where high-resolution chest tomography has a prominent role. Key words: smoking; emphysema; interstitial lung diseases; Langerhans cell histiocytosis

Humans , Male , Adult , Aged , Histiocytosis, Langerhans-Cell , Lung Diseases, Interstitial , Emphysema , Tobacco Use Disorder
Journal of the ASEAN Federation of Endocrine Societies ; : 149-153, 2023.
Article in English | WPRIM | ID: wpr-1003695


@#Thyroid involvement in Langerhans Cell Histiocytosis (LCH) is rare. We report a 10-year-old Filipino male who presented with a rapidly enlarging goiter. Computed tomography scan showed thyroid and bilateral submandibular masses with malignant features, pulmonary blebs and hepatic cysts. Ultrasound-guided core needle biopsy findings were consistent with LCH and chemotherapy was initiated. This case demonstrates that LCH should be considered in patients with goiter. Multidisciplinary management is warranted to achieve proper diagnosis and institute timely treatment.

Histiocytosis, Langerhans-Cell , Thyroid Gland
Odovtos (En línea) ; 24(2)ago. 2022.
Article in English | LILACS, SaludCR | ID: biblio-1386588


Abstract Langerhans cells histiocytosis is a rare disease characterized by monoclonal proliferation and migration of special dendritic cells in a variety of organs, most commonly appears eosinophilic granuloma localized, often solitary, and bone lesions that occurs predominantly in pediatric patients. Although is most prevalent in children under the age of 15, this disorder presents in all ages and occurs at a rate of 2 to 5 cases per million per year. LCH is a complex entity; the clinic manifestations can mimic other common conditions and therefore a comprehensive evaluation is indicated. Since oral manifestations are frequent, the early diagnose of this pathology could be detected by dental professionals. The aim of this case report is to describe a case of LCH who initially was misdiagnosed and treated for a dental infection. This disease requires accurate histopathological diagnosis and timely treatment; hence it is necessary to raise awareness among dentists to avoid misdiagnose of oral manifestations of LCH.

Resumen La histiocitosis de las células de Langerhans es una enfermedad poco frecuente que se caracteriza por la proliferación monoclonal y la migración de células dendríticas especiales en una variedad de órganos; lo más común es que aparezca un granuloma eosinofílico localizado, a menudo solitario, así como lesiones óseas que se producen predominantemente en pacientes pediátricos. Aunque es más frecuente en los niños menores de 15 años, este trastorno se presenta en todas las edades y se produce a una tasa de 2 a 5 casos por millón al año. La HCL es una entidad compleja; las manifestaciones clínicas pueden imitar otras afecciones comunes y, por lo tanto, se indica una evaluación exhaustiva. Dado que las manifestaciones orales son frecuentes, el diagnóstico precoz de esta patología podría ser detectado por los profesionales de la odontología. El objetivo de este reporte de caso es describir un caso de HCL que inicialmente fue mal diagnosticado y tratado por una infección dental. Esta enfermedad requiere un diagnóstico histopatológico preciso y un tratamiento oportuno; por lo tanto, es necesario sensibilizar a los dentistas para evitar un diagnóstico erróneo de las manifestaciones orales de la HCL.

Humans , Male , Child , Histiocytosis, Langerhans-Cell/diagnosis
Journal of Central South University(Medical Sciences) ; (12): 334-343, 2022.
Article in English | WPRIM | ID: wpr-928975


OBJECTIVES@#Pulmonary Langerhans cell histiocytosis (PLCH) is a clonal disease, characterized by proliferation of Langerhans cells that derived from bone marrow infiltrating the lungs and other organs. Due to the rarity of the disease, the current understanding of the disease is insufficient, often misdiagnosed or missed diagnosis. This study aims to raise clinicians' awareness for this disease via summarizing the clinical characteristics, imaging features, and treatment of PLCH.@*METHODS@#We retrospectively analyzed clinical and follow-up data of 15 hospitalized cases of PLCH from September 2012 to June 2021 in the Second Xiangya Hospital of Central South University.@*RESULTS@#The age of 15 patients (9 men and 6 women, with a sex ratio of 3 to 2) was 21-52 (median 33) years. Among them, 8 had a history of smoking and 5 suffered spontaneous pneumothorax during disease course. There were 3 patients with single system PLCH and 12 patients with multi-system PLCH, including 7 patients with pituitary involvement, 7 patients with lymph node involvement, 6 patients with bone involvement, 5 patients with liver involvement, 2 patients with skin involvement, 2 patients with thyroid involvement, and 1 patients with thymus involvement. The clinical manifestations were varied but non-specific. Respiratory symptoms mainly included dry cough, sputum expectoration, chest pain, etc. Constitutional symptoms included fever and weight loss. Patients with multi-system involvement experienced symptoms such as polyuria-polydipsia, bone pain, and skin rash. All patients were confirmed by pathology, including 6 by lung biopsy, 3 by bone biopsy, 2 by lymph node biopsy, and 4 by liver, skin, suprasternal fossa tumor, or pituitary stalk biopsy. The most common CT findings from this cohort of patients were nodules and/or cysts and nodular and cystic shadows were found in 7 patients. Three patients presented simple multiple cystic shadows, 3 patients presented multiple nodules, and 2 patients presented with single nodules and mass shadows. Pulmonary function tests were performed in 4 patients, ventilation dysfunction was showed in 2 patients at the first visit. Pulmonary diffusion function tests were performed in 4 patients and showed a decrease in 3 patients. Smoking cessation was recommended to PLCH patients with smoking history. Ten patients received chemotherapy while 2 patients received oral glucocorticoid therapy. Among the 11 patients with the long-term follow-up, 9 were in stable condition.@*CONCLUSIONS@#PLCH is a neoplastic disease closely related to smoking. The clinical manifestations and laboratory examination are not specific. Pneumothorax could be the first symptom which is very suggestive of the disease. Definitive diagnosis relies on histology. There is no unified treatment plan for PLCH, and individualized treatment should be carried out according to organ involvement. Early smoking cessation is essential. Chemotherapy is the main treatment for rapidly progressing PLCH involved multiple organs. All diagnosed patients can be considered for the detection of BRAFV600E gene and relevant targeted therapies have been implemented recently.

Adult , Female , Humans , Male , Cysts , Histiocytosis, Langerhans-Cell/therapy , Lung/pathology , Retrospective Studies , Smoking/adverse effects , Smoking Cessation
Journal of Experimental Hematology ; (6): 970-974, 2022.
Article in Chinese | WPRIM | ID: wpr-939718


Langerhans cell histiocytosis (LCH) is a rare proliferative disease dominated by the proliferation of Langerhans cells, which is inflammatory myeloid neoplasms. Its clinical manifestations are variable, occurring at any age and at any site, and it is rarer in adults than in children. The gold standard for diagnosis is histopathological biopsy. Due to the rarity of adult LCH and the heterogeneity of this disease, treatment of adult LCH should be developed according to the extent of the disease and risk stratification. With the discovery of MAPK, PI3K and c-KIT signaling pathway activation, especially BRAF V600E and MAP2K1 mutations, targeted therapy has become a hot spot for therapeutic research. Meanwhile, the discovery of high expression of M2-polarized macrophages and Foxp3+ regulatory T cells (Treg) in LCH has provided an important basis for the immunotherapy. In this article, we will focus on reviewing the latest research progress in the treatment of adult LCH in recent years, and provide a reference for clinical research on the treatment of adult LCH patients.

Adult , Child , Humans , Histiocytosis, Langerhans-Cell/therapy , Mutation , Proto-Oncogene Proteins B-raf/metabolism , Signal Transduction , T-Lymphocytes, Regulatory/pathology
Journal of Experimental Hematology ; (6): 943-949, 2022.
Article in Chinese | WPRIM | ID: wpr-939714


OBJECTIVE@#To observe the efficacy and prognosis of cladribine (2-CdA) combined with cytarabine (Ara-C) regimen in the treatment of relapsed refractory Langerhans cell histiocytosis (LCH) in children.@*METHODS@#Nine patients with relapsed refractory LCH treated with the 2-CdA combined with Ara-C regimen in the Department of Hematology and Oncology of Wuhan Children's Hospital from July 2014 to February 2020 were retrospectively analyzed, and the efficacy and disease status were evaluated according to the Histiocyte Society Evaluation and Treatment Guidelines (2009) and the Disease Activity Score (DAS), the drug toxicity were evaluated according to the World Health Organization(WHO) grading criteria for chemotherapy. All patients were followed up for survival status and disease-related sequelae.@*RESULTS@#Before the treatment combining 2-CdA and Ara-C, 7 of 9 patients were evaluated as active disease worse (ADW), and 2 as active disease stable (ADS) with a median disease activity score of 8 (4-15). Of 9 patients, 6 cases achieved non active disease (NAD) and 3 achieved active disease better (ADB) with a median disease activity score of 0 (0 to 5) after 2-6 courses of therapy. All 9 patients experienced WHO grade IV hematologic toxicity and 3 patients had hepatobiliary adverse effects (WHO grade I~II) after treatment. The median follow-up time was 31(1 to 50) months with all 9 patients survived, 3 of the 9 patients experienced sequelae to the disease with 2 combined liver cirrhosis as well as cholestatic hepatitis and 1 with oral desmopressin acetate tablets for diabetes insipidus.@*CONCLUSION@#2-CdA combined with Ara-C is an effective regimen for the treatment of recurrent refractory LCH in children, and the main adverse effect is hematologic toxicity, which is mostly tolerated in children. Early treatment with this regimen may be considered for patients with multisystem LCH with risky organ involvement who have failed first-line therapy and for patients with relapse.

Child , Humans , Cladribine/adverse effects , Cytarabine , Histiocytosis, Langerhans-Cell/drug therapy , Recurrence , Retrospective Studies
Ibom Medical Journal ; 15(2): 183-190, 2022. figures
Article in English | AIM | ID: biblio-1380116


Mandibular aggressive central giant cell granuloma is a rare non-neoplastic giant cell tumour characterised by pain, bone destruction, tooth root resorption, jawbone cortical perforation, and high recurrence rate. This is a case of a 10-year-old boy who presented to the Dental Surgical outpatient clinic of University of Uyo Teaching Hospital with a three-year history of left jaw swelling. The clinical diagnosis was fibrous dysplasia of the left hemi-mandible. Consequently, left hemi-mandibulectomy was performed, and subsequent histopathological diagnosis was aggressive central giant cell granuloma of the mandible. This article presents this rare diagnosis and explores its classification, aetiopathogenesis, clinico-pathological features and management.

Humans , Male , Female , Granuloma, Giant Cell , Histiocytosis, Langerhans-Cell , Bone Diseases , Giant Cells , Mandible
Biomédica (Bogotá) ; 41(3): 396-402, jul.-set. 2021. graf
Article in Spanish | LILACS | ID: biblio-1345390


Resumen La histiocitosis de células de Langerhans comprende un grupo heterogéneo de enfermedades inflamatorias cuyos principales componentes celulares son las células dendríticas y los macrófagos. El infiltrado inflamatorio puede afectar la piel y otros órganos, y el resultado clínico varía de leve a letal, dependiendo del subconjunto de células involucradas y el compromiso multisistémico. La demora en el diagnóstico puede ocurrir debido a su presentación inespecífica y a que los médicos tratantes no suelen sospecharla. Se reporta el caso de una lactante mayor a la cual, a pesar de múltiples consultas con síntomas inespecíficos pero característicos de la enfermedad, solamente se le pudo hacer el diagnóstico gracias a los hallazgos histopatológicos.

Abstract Histiocytosis comprises a heterogeneous group of inflammatory diseases whose main cellular components are dendritic cells and macrophages. The inflammatory infiltrate can affect the skin and other organs and the clinical outcome varies from mild to fatal depending on the involved cell subset and multisystemic compromise. Delay in diagnosis may occur due to its non-specific presentation and to a low suspicion on the part of the clinician. We report the case of an infant who despite multiple consultations with nonspecific but characteristic symptoms of the disease was only finally diagnosed thanks to histopathological findings.

Histiocytosis, Langerhans-Cell , Pediatrics , Histiocytosis , Dermatitis, Seborrheic , Conjunctivitis
Rev. odontopediatr. latinoam ; 11(2): 220204, 2021. graf, tab
Article in Spanish | LILACS, COLNAL | ID: biblio-1417087


La Histiocitosis de células de Langerhans (HCL), es una enfermedad rara, caracterizada por la proliferación clonal agresiva de células de Langerhans dendríticas de la médula ósea. La enfermedad crea lesiones osteolíticas en donde las manifestaciones orales usualmente están presentes. El objetivo de este reporte de caso es, presentar el seguimiento de cinco años de un caso diagnosticado en el 2014 y una revisión sistemática de literatura de las manifestaciones orales de HCL. Para la revisión sistemática, el argumento de búsqueda con palabras claves como HCL, histiocitosis X y manifestaciones orales, fueron conducidas en cinco bases de datos como PUBMED, LILACS, EBSCO, OVID y SCOPUS. Las manifestaciones orales más comunes son inflamación, enrojecimiento y pérdida de hueso en las áreas afectadas. Es importante mantener un seguimiento periódico en el consultorio dental de los casos de HCL en la población pediátrica. La HCL usualmente presenta manifestaciones orales que pueden ser un signo de diagnóstico temprano de esta condición, especialmente en la población pediátrica.

A histiocitose de células de Langerhans (HCL) é uma doença rara caracterizada pela proliferação clonal agressiva de células dendríticas de Langerhans da medula óssea. A doença cria lesões osteolíticas onde as manifestações orais geralmente estão presentes. O objetivo deste relato de caso é apresentar o seguimento de cinco anos de um caso diagnosticado em 2014 e uma revisão sistemática da literatura sobre as manifestações orais da HCL. Para a revisão sistemática, a busca de argumento com palavras-chave como LCH, histiocytosis X e oral manifestations, foi realizada em cinco bases de dados como PUBMED, LILACS, EBSCO, OVID e SCOPUS. As manifestações orais mais comuns são inflamação, vermelhidão e perda óssea nas áreas afetadas. É importante monitorar regularmente os casos de HCL na população pediátrica no consultório odontológico. A HCL geralmente apresenta manifestações orais que podem ser um sinal diagnóstico precoce dessa condição, principalmente na população pediátrica

Langerhans cell histiocytosis (LCH) is a rare disease characterized by aggressive clonal proliferation of dendritic Langerhans cells from the bone marrow. The disease creates osteolytic lesions where oral manifestations are usually present. The objective of this case report is to present the five-year follow-up of a case diagnosed in 2014 and a systematic review of the literature on the oral manifestations of LCH. For the systematic review, the search argument with keywords such as LCH, histiocytosis X and oral manifestations, were conducted in five databases such as PUBMED, LILACS, EBSCO, OVID and SCOPUS. The most common oral manifestations are inflammation, redness, and bone loss in the affected areas. It is important to regularly monitor LCH cases in the pediatric population in the dental office. LCH usually presents oral manifestations that can be an early diagnostic sign of this condition, especially in the pediatric population

Humans , Child, Preschool , Child , Adolescent , Langerhans Cells , Histiocytosis, Langerhans-Cell , Oral Manifestations , Dendritic Cells , Rare Diseases , Dental Offices , Early Diagnosis , Literature
Med. lab ; 25(4): 721-734, 2021. Tabs, ilus
Article in Spanish | LILACS | ID: biblio-1370934


La histiocitosis de células de Langerhans (HCL) es una enfermedad que puede afectar a pacientes de cualquier edad, siendo en adultos un trastorno poco común de etiología desconocida, que ocurre predominantemente en fumadores jóvenes, sin diferencias en género. Aunque ciertas particularidades de la enfermedad pueden compartirse con las manifestaciones presentes en la población pediátrica, la proporción de casos con afectación pulmonar es mucho mayor en adultos. A menudo evoluciona a través de brotes sucesivos y su gravedad varía desde formas benignas hasta potencialmente mortales. Algunos pacientes desarrollan un importante deterioro funcional con repercusión psicosocial, que impacta en la calidad de vida y se asocia a discapacidad prolongada. La clave diagnóstica estará determinada por el antecedente de tabaquismo, la presencia de nódulos, nódulos cavitados y quistes de paredes gruesas y delgadas en la tomografía computarizada de tórax de alta resolución (TACAR). Sin embargo, el diagnóstico definitivo requiere la identificación de granulomas de células de Langerhans, que generalmente se logra mediante la realización de una biopsia pulmonar y su estudio histopatológico e inmunohistoquímico. En la actualidad, podríamos considerar a esta entidad como una enfermedad huérfana, de la cual aún no se tiene claridad del mecanismo patogénico, y que, por ende, aún no dispone de estrategias terapéuticasespecíficas. El objetivo de esta revisión está centrado en la aproximación diagnóstica y terapéutica de la histiocitosis de células de Langerhans en adultos,que permita facilitar su reconocimiento en etapas tempranas y mejorar el pronóstico en las personas que la padecen

Langerhans cell histiocytosis (LCH) is a disease that can affect patients of any age, but in adults it is a rare disorder of unknown etiology that occurs predominantly in young smokers, without differences in gender. Although certain peculiarities of the disease can be the same than in the pediatric population, the proportion of cases with pulmonary involvement is much higher in adults. It often evolves through successive flare-ups and its severity ranges from benign tolife-threatening. Some patients develop significant functional impairment with psychosocial repercussions, that impact the quality of life and are associated with prolonged disability. The diagnostic key will be determined by the history of smoking, and the presence of nodules, cavitated nodules, and thick and thin-walled cysts on high-resolution chest computed tomography (HRCT). However, the definitive diagnosis requires the identification of Langerhans cell granulomas, which is generally achieved by performing a lung biopsy and its histopathological and immunohistochemical study. Today, we could consider this a rare entity, of which there is no clear pathogenic mechanism, and therefore, does not have yet specific therapeutic strategies. The purpose of this review is centered on the diagnostic and therapeutic approach of Langerhans cell histiocytosis in adults, which allows its recognition in early stages and improve the prognosis in people who suffer from it

Humans , Histiocytosis, Langerhans-Cell , Tobacco Use Disorder , Immunohistochemistry , Cysts , Multiple Pulmonary Nodules
Chinese Journal of Contemporary Pediatrics ; (12): 98-102, 2021.
Article in Chinese | WPRIM | ID: wpr-879816


A girl, aged 22 months, attended the hospital due to recurrent vulvar rashes for more than half a year. Skin biopsy showed Langerhans cell histiocytosis, and evaluation of systemic conditions showed no systemic involvement. Therefore, the girl was diagnosed with Langerhans cell histiocytosis (skin type). In conclusion, for rashes on the vulva alone, if there are no specific clinical manifestations, the possibility of Langerhans cell histiocytosis should be considered after molluscum contagiosum, sexually transmitted diseases, and Fordyce disease are excluded.

Female , Humans , Infant , Developmental Disabilities , Exanthema/etiology , Histiocytosis, Langerhans-Cell , Vulvar Diseases/diagnosis
Autops. Case Rep ; 11: e2021253, 2021. tab, graf
Article in English | LILACS | ID: biblio-1153186


Objective : Langerhans cell histiocytosis (LCH) is an uncommon entity of unknown etiology. It contains a wide range of clinical presentations. The discovery of oncogenic BRAF V600E mutation in LCH has provided additional evidence that LCH is a neoplasm. Papillary thyroid carcinoma is the most common cancer of the thyroid characterized by a high incidence of BRAF V600E mutations. LCH with concomitant PTC is rare, with few cases reported in the literature. Cases summary We identified two cases of LCH with concomitant papillary thyroid carcinoma in adult patients. The first was a 49-year-old female with a thyroid nodule diagnosed with papillary thyroid carcinoma. Later, the patient had a left neck mass; Ultrasound-guided lymph node FNA was diagnosed with Langerhans histiocytosis. Subsequently, a chest CT scan revealed signs of Langerhans cell histiocytosis in the lung. The second case refers to a 69-year-old male who presented with a left thyroid nodule diagnosed on FNA cytology as papillary thyroid carcinoma. The patient was found to have multiple bone lytic lesions. Biopsies revealed Langerhans cell histiocytosis. Later, the patient experienced LCH involvement of the bone marrow with associated secondary myelofibrosis. Conclusions LCH is rare in adults; the association with papillary thyroid carcinoma is reported and should be considered in the presence of Langerhans cell groups along with PTC, whether in the thyroid gland or cervical lymph nodes. Once LCH has been diagnosed, pulmonary involvement should also be investigated. This will direct treatment plans for patients with pulmonary or systemic disease involvement.

Humans , Male , Female , Middle Aged , Aged , Histiocytosis, Langerhans-Cell/pathology , Thyroid Cancer, Papillary/pathology , Mutation
Autops. Case Rep ; 10(2): e2020154, Apr.-June 2020. tab, graf
Article in English | LILACS | ID: biblio-1131819


Langerhans cell histiocytosis (LCH), a disorder of antigen-presenting cells, is the commonest disorder of the mononuclear phagocytic system. Diagnosis is always challenging due to heterogeneous clinical presentation. However, with the evolution and better understanding of its biology, many of these children are being diagnosed early and offered appropriate therapy. Despite these advances, in developing countries, an early diagnosis is still challenging due to resource constraints for specialized tests. As a result, many patients succumb to their disease. Autopsy data on LCH is notably lacking in the literature. We sought to analyze the clinical (including mutational) and morphologic features at autopsy in six proven cases of LCH. This study includes a detailed clinico-pathological and mutational analysis of 6 proven cases of LCH. Presence of BRAF V600E mutation was assessed by both Real Time PCR and Sanger sequencing. A varied spectrum of organ involvement was noted with some rare and novel morphological findings, like nodular bronchiolocentric infiltration of LCH cells, lymphovascular emboli of LCH cells, and paucity of eosinophils within the infiltrate; these features have not been described earlier. Surprisingly, all cases were negative for BRAF V600E mutation on both RQ-PCR and Sanger sequencing. The present study is perhaps the first autopsy series on LCH. This extensive autopsy analysis represents a correlation of pathological features with clinical symptoms which provides clues for a timely diagnosis and appropriate therapeutic intervention. Also, our findings hint at the low frequency of BRAF V600E mutation in our LCH patients.

Humans , Male , Infant , Child, Preschool , Histiocytosis, Langerhans-Cell/pathology , Autopsy , Proto-Oncogene Proteins c-abl , Mitogen-Activated Protein Kinase Kinases , Early Diagnosis
Journal of Experimental Hematology ; (6): 2079-2083, 2020.
Article in Chinese | WPRIM | ID: wpr-880018


OBJECTIVE@#To observe the clinical and laboratory characteristics of adult Langerhans cell histiocytosis(LCH) patients and to analyze the influencing factors of its prognosis.@*METHODS@#The clinical and laboratory charac-teristics of 38 adult LCH patients treated in our hospital from January 2010 to August 2019 were retrospective analyzed, and the clinical prognosis of the patients was analyzed.@*RESULTS@#The median age of 38 patients was 41 (21-65) years old, and the ratio of male and female was about 2∶1. Among 38 patients, 44.7% (17/38) were involved in multiple systems, and 31.6% (12/38) were involved in high-risk organs (including liver, lung, hematopoietic system or spleen). The bone involvement was the most common (21/38, 55.3%), and the most common clinical symptom was pain (19/38, 50.0%). The result of laboratory showed that anemia (4/38,10.5%), thrombocytopenia (1/38,2.6%), neutropenia (2/38,5.3%), lymphopenia (6/38,15.8%), monocytosis (11/38,28.9%), C-reactive protein increasing (6/21,28.6%), erythrocyte sedimentation rate increasing (10/18, 55.3%), and ferritin protein increasing (9/17, 55.3%). The median follow-up time was 53 months, and a total of 5 patients were died. The 10-year overall survival rate of patients with single-system involvement was 100%, which was significantly higher than that of patients with multiple-system involvement (70.1%) (P=0.0078). The prognosis of patients without risk-organ involvement was better than that of patients with risk-organ involvement (10-year overall survival rate: 100% vs 60.6%) (P=0.0007). Further analysis showed that in addition to multiple-system involvement and risk-organ involvement, the increase of peripheral blood monocyte cells and the increase of ferritin protein were also associated with poorer prognosis of the patients.@*CONCLUSION@#The multiple system involve-ment and risk-organ involvement, the increasing of monocyte cells and the increasing of ferritin protein were the independent risk factors of adult LCH patients.

Adult , Aged , Female , Humans , Infant , Male , Middle Aged , Histiocytosis, Langerhans-Cell , Laboratories , Patients , Prognosis , Retrospective Studies
Journal of Central South University(Medical Sciences) ; (12): 96-101, 2020.
Article in English | WPRIM | ID: wpr-812981


Langerhans cell histiocytosis (LCH) is a rare and unexplained disease that can involve in any organ or system in the body and displays a variety of clinical manifestations. A 31-year-old man, who had a more than 10-year smoke history, initially presented dry cough, polydipsia and diuresis, with recurrent spontaneous pneumothorax. Pulmonary high-resolution computed tomography showed diffuse cystic and nodular lesions. Langerhans cell histiocytosis was confirmed by a transbronchial cryobiopsy. The disease is involved in the lung, pituitary, thyroid, liver, lymph node, and skin. Glucocorticoid or systemic chemotherapy is commonly used in the treatment for this disease. BRAF gene mutation inhibitor is a new direction for the treatment.

Adult , Humans , Male , Histiocytosis, Langerhans-Cell , Lung , Skin , Thyroid Gland , Tomography, X-Ray Computed